Showing results (171-180 of 213) with videos related to

Sort By:
Pageof 22
Clinical and Vaccine Immunology : CVI|March 22, 2013
A prime-boost strategy using the novel vaccine candidate, LemA, protects hamsters against leptospirosisDaiane D Hartwig, Karine M Forster, Thaís L Oliveira, et al.
The British Journal of Nutrition|April 23, 2013
Calcium supplements and cancer risk: a meta-analysis of randomised controlled trialsSarah M Bristow, Mark J Bolland, Graeme S MacLennan, et al.
Journal of Microbiological Methods|September 8, 2009
Efficient site-directed mutagenesis using an overlap extension-PCR method for expressing Mycoplasma hyopneumoniae genes in Escherichia coliSimone Simionatto, Silvana B Marchioro, Vanessa Galli, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|February 9, 2017
Long-Term Randomized Trial of Intensive Versus Symptomatic Management in Paget's Disease of Bone: The PRISM-EZ StudyAdrian Tan, Kirsteen Goodman, Allan Walker, et al.
Human Vaccines|November 4, 2011
Recombinant vaccines against leptospirosisOdir A Dellagostin, André A Grassmann, Daiane D Hartwig, et al.
Clinical and Vaccine Immunology : CVI|March 15, 2013
A conserved region of leptospiral immunoglobulin-like A and B proteins as a DNA vaccine elicits a prophylactic immune response against leptospirosisKarine M Forster, Daiane D Hartwig, Fabiana K Seixas, et al.
Rapid Communications in Mass Spectrometry : RCM|September 26, 2017
Characterization of dicarboxylic naphthenic acid fraction compounds utilizing amide derivatization: Proof of conceptKevin A Kovalchik, Matthew S MacLennan, Kerry M Peru, et al.
Memorias Do Instituto Oswaldo Cruz|December 18, 2015
DNA prime-protein boost based vaccination with a conserved region of leptospiral immunoglobulin-like A and B proteins enhances protection against leptospirosisKarine M Forster, Daiane D Hartwig, Thaís L Oliveira, et al.
The British Journal of Ophthalmology|April 20, 2004
Comparison of autologous serum eye drops with conventional therapy in a randomised controlled crossover trial for ocular surface diseaseB A Noble, R S K Loh, S MacLennan, et al.
Pageof 22